噻托溴铵与布地奈德联用治疗ACOS患者的效果及对FeNO水平的影响

Effectiveness of tiotropium bromide in combination with budesonide in the treatment of patients with ACOS and the effect on FeNO levels

目的:分析哮喘-慢阻肺重叠综合征(ACOS)患者使用噻托溴铵联合布地奈德治疗的综合疗效以及对患者呼出气一氧化氮(FeNO)水平的影响。方法:选取2022年3月—2023年3月临沂市中心医院收治的80例ACOS患者为研究对象,采用随机数字表法分为观察组与对照组各40例。观察组患者给予基础治疗+噻托溴铵+布地奈德,对照组患者给予基础治疗+布地奈德。比较两组患者的治疗效果。结果:观察组患者综合疗效以及治疗后肺功能指标、生活质量评分、6 min步行距离均高于对照组,治疗后FeNO水平小于对照组,差异有统计学意义(P<0.05)。结论:对ACOS患者通过采取噻托溴铵联合布地奈德治疗,更有利于提升综合疗效,改善患者肺部功能、运动耐力与生活质量,降低FeNO水平,临床应用价值较高。

Objective To analyze the comprehensive efficacy of the combined treatment of tiotropium bromide and budesonide in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS)and its impact on fractional exhaled nitric oxide(FeNO)levels.Methods Eighty ACOS patients admitted to Linyi Central Hospital from March 2022 to March 2023 were selected as the research subjects.They were randomly divided into an observation group and a control group,with 40 cases in each group.The observation group received basic treatment plus tiotropium bromide and budesonide,while the control group received basic treatment plus budesonide.The treatment effects of the two groups were compared.Results The comprehensive efficacy of the observation group,as well as post-treatment lung function indicators,quality of life scores,and 6-minute walking distance,were higher than those of the control group.The post-treatment FeNO level was lower in the observation group than that in the control group,and the differences were statistically significant(P<0.05).Conclusions In the treatment of ACOS patients,the use of tiotropium bromide combined with budesonide is more conducive to improving comprehensive efficacy,enhancing lung function,exercise endurance,and quality of life,and reducing FeNO levels.It has high clinical application value.